Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/431
Title: ProSPER-82: A prospective phase II trial investigating SpaceOAR hydrogel in patients with prostate cancer receiving dose escalated radiotherapy to 82Gy trial-a radiotherapy planning perspective of clinical implementation.
Epworth Authors: Mastroianni, Bianca
Keywords: Epworth Radiation Oncology, Melbourne, Victoria, Australia
Radiation Oncology
Oncology, Radiation
Computerized Tomography, X-Ray
Magnetic Resonance Imaging
Radiation Therapy
Radiotherapy
Prostate Cancer
Cancer of the Prostate
Neoplasms, Prostate
Hydrogel
Radiotherapy Planning, Computer-Assisted
Computer-Assisted Radiotherapy Planning
Planning, Computer-Assisted Radiotherapy
Prospective Phase II Trial
IMRT
Intensity Modulated Radiotherapy
Issue Date: Sep-2014
Citation: Journal of Medical Imaging and Oncology Conference Publication (var. pagings). 58 (pp 282), September 2014.
Conference: 2014 Combined Scientific Meeting: Imaging and Radiation in Personalised Medicine.
Conference Location: Melbourne, Victoria, Australia
Abstract: Aim: ProSPER-82: A Prospective Phase II Trial Investigating SpaceOAR® Hydrogel in Patients with Prostate Cancer Receiving Dose Escalated Radiotherapy to 82Gy (ProSPER-82) aims to use Intensity Modulated Radiotherapy (IMRT), following the insertion of SpaceOAR®, to dose escalate men undergoing treatment for clinically localised prostate cancer, aiming to treat to doses of 82Gy in 41 fractions (1). This paper will discuss rectal wall doses achieved for the first 10 patients pre and post. Methods and materials: Additional scans and IMRT plans are required for the study, as described in the trial schema (Fig. 1). A computed tomography (CT) scan pre SpaceOAR® insertion is acquired, in the treatment position (supine, arms on chest, two square sponges under the head, pelvic board with personalised lower half body vacfix). Skin tattoos are placed at setup reference points during this appointment. SpaceOAR® is inserted into the retro prostatic space, introducing a physical gap between the prostate and Results: ARJ wall and rectal wall doses were compared for the pre SpaceOAR® 78Gy plan and the post SpaceOAR® 78Gy and 82Gy plans, at the dose points that current departmental protocol specifies as dose constraints. Figure 3 displays the mean doses for the ARJ wall. The minimum (Fig. 4) and maximum (Fig. 5) doses achieved within the cohort at each dose point were also compared, and the same trend was clearly seen, where in every case analysed, the post SpaceOAR® plans delivered less dose to Conclusion: A comparison of the first 10 patients enrolled into the ProSPER 82Gy trial confirm that SpaceOAR® allows for dose escalation to 82Gy in 41 fractions whilst delivering significantly lower doses to the rectal wall and ARJ wall.
URI: http://hdl.handle.net/11434/431
DOI: 10.1594/ranzcr2014/R-0257
Type: Conference Paper
Type of Clinical Study or Trial: Prospective Phase II Trial
Appears in Collections:Radiation Oncology
Cancer Services
Epworth Prostate Centre
UroRenal, Vascular

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.